Sarcopenia as a Predictor of Prognosis in Early Stage Ovarian Cancer

Background: To identify sarcopenia as a predictive prognostic factor of ovarian cancer in terms of survival outcome in patients with early-stage ovarian cancer. Methods: Data of Konkuk University Medical Center from March 2002 to December 2017 were reviewed retrospectively. Eighty-two patients who underwent surgery due to early-stage (International Federation of Gynecology and Obstetrics stage I/II) ovarian cancer and had computed tomography (CT) images taken at the initial diagnosis were included. The initial CT scan images were analyzed with SliceOmatic software (TomoVision). A sarcopenia cutoff value was defined as a skeletal muscle index of <= 38.7 cm(2)/m(2). Overall survival (OS) times were compared according to the existence of sarcopenia, and subgroup analyses were performed. Results: A Kaplan-Meier analysis showed a significant survival disadvantage for patients with early-stage ovarian cancer when they had sarcopenia (P< 0.001; log-rank test). Sarcopenia remained a significant prognostic factor for OS in early-stage ovarian cancer, in a Cox proportional hazards model regression analysis (HR, 21.9; 95% CI, 2.0-199.9; P= 0.006). Conclusion: This study demonstrated that sarcopenia was predictive of OS in patients with early-stage ovarian cancer. Further prospective studies with a larger number of patients are warranted to determine the extent to which sarcopenia can be used as a prognostic factor in ovarian cancer.

Automated summary

This study retrospectively analyzed data from 82 patients with early-stage ovarian cancer and found that sarcopenia can serve as a predictive prognostic factor for survival outcome in these patients. Further prospective studies with larger sample sizes are needed to confirm the extent to which sarcopenia can be used as a prognostic factor in ovarian cancer.